Standard Review for Gileads Oncology Candidate Zacks.com The patients were refractory to both Roche's (RHHBY) Rituxan (rituximab) and to chemotherapy inclusive alkylating-agent. A decision from the FDA is expected by Sep 11, 2014. Apart from iNHL, idelalisib is also being evaluated in other oncology ... Gilead's Idelalisib NDA accepted by US FDA for the treatment of refractory ... |
